Eligible patients in SwedeHF, compared to the GALACTIC-HF study population, were older (mean age 74 vs. 65 years), more likely female (27% vs. 21%), more likely in NYHA classes III-IV (63% vs. 47%), had higher NT-proBNP levels (median 4,250 vs. 1,971 pg/mL), and with higher prevalence of atrial fibrillation (63% vs. 42%) and ischemic heart disease (69% vs. 62%), but lower prevalence of hypertension (65% vs. 70%) [10]. The gene discussed is NPPB; the disease is hydrops fetalis.